The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
<h4>Unlabelled</h4>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT),...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0116306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726495543525376 |
|---|---|
| author | Ma Somsouk Richard M Dunham Michelle Cohen Rebecca Albright Mohamed Abdel-Mohsen Teri Liegler Jeffrey Lifson Michael Piatak Robert Gorelick Yong Huang Yuaner Wu Priscilla Y Hsue Jeffrey N Martin Steven G Deeks Joseph M McCune Peter W Hunt |
| author_facet | Ma Somsouk Richard M Dunham Michelle Cohen Rebecca Albright Mohamed Abdel-Mohsen Teri Liegler Jeffrey Lifson Michael Piatak Robert Gorelick Yong Huang Yuaner Wu Priscilla Y Hsue Jeffrey N Martin Steven G Deeks Joseph M McCune Peter W Hunt |
| author_sort | Ma Somsouk |
| collection | DOAJ |
| description | <h4>Unlabelled</h4>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm3 and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. Compared to placebo-treated subjects, mesalamine-treated subjects did not experience any significant change in the percent CD38+HLA-DR+ peripheral blood CD4+ and CD8+ T cells at week 12 (P = 0.38 and P = 0.63, respectively), or in the CD4+ T cell count at week 12 (P = 0.83). The percent CD38+HLA-DR+ CD4+ and CD8+ T cells also did not change significantly in rectal tissue (P = 0.86, P = 0.84, respectively). During the period of mesalamine administration, plasma sCD14, IL-6, D-dimer, and kynurenine to tryptophan ratio were not changed significantly at week 12 and were similarly unchanged at week 24. This study suggests that, at least under the conditions studied, the persistent immune activation associated with HIV infection is not impacted by the anti-inflammatory effects of mesalamine.<h4>Trial registration</h4>ClinicalTrials.gov NCT01090102. |
| format | Article |
| id | doaj-art-df60e9cf8f774c4a8d26c8097c573521 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-df60e9cf8f774c4a8d26c8097c5735212025-08-20T03:10:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11630610.1371/journal.pone.0116306The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.Ma SomsoukRichard M DunhamMichelle CohenRebecca AlbrightMohamed Abdel-MohsenTeri LieglerJeffrey LifsonMichael PiatakRobert GorelickYong HuangYuaner WuPriscilla Y HsueJeffrey N MartinSteven G DeeksJoseph M McCunePeter W Hunt<h4>Unlabelled</h4>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm3 and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. Compared to placebo-treated subjects, mesalamine-treated subjects did not experience any significant change in the percent CD38+HLA-DR+ peripheral blood CD4+ and CD8+ T cells at week 12 (P = 0.38 and P = 0.63, respectively), or in the CD4+ T cell count at week 12 (P = 0.83). The percent CD38+HLA-DR+ CD4+ and CD8+ T cells also did not change significantly in rectal tissue (P = 0.86, P = 0.84, respectively). During the period of mesalamine administration, plasma sCD14, IL-6, D-dimer, and kynurenine to tryptophan ratio were not changed significantly at week 12 and were similarly unchanged at week 24. This study suggests that, at least under the conditions studied, the persistent immune activation associated with HIV infection is not impacted by the anti-inflammatory effects of mesalamine.<h4>Trial registration</h4>ClinicalTrials.gov NCT01090102.https://doi.org/10.1371/journal.pone.0116306 |
| spellingShingle | Ma Somsouk Richard M Dunham Michelle Cohen Rebecca Albright Mohamed Abdel-Mohsen Teri Liegler Jeffrey Lifson Michael Piatak Robert Gorelick Yong Huang Yuaner Wu Priscilla Y Hsue Jeffrey N Martin Steven G Deeks Joseph M McCune Peter W Hunt The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS ONE |
| title | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. |
| title_full | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. |
| title_fullStr | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. |
| title_full_unstemmed | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. |
| title_short | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. |
| title_sort | immunologic effects of mesalamine in treated hiv infected individuals with incomplete cd4 t cell recovery a randomized crossover trial |
| url | https://doi.org/10.1371/journal.pone.0116306 |
| work_keys_str_mv | AT masomsouk theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT richardmdunham theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT michellecohen theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT rebeccaalbright theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT mohamedabdelmohsen theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT teriliegler theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT jeffreylifson theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT michaelpiatak theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT robertgorelick theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT yonghuang theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT yuanerwu theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT priscillayhsue theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT jeffreynmartin theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT stevengdeeks theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT josephmmccune theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT peterwhunt theimmunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT masomsouk immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT richardmdunham immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT michellecohen immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT rebeccaalbright immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT mohamedabdelmohsen immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT teriliegler immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT jeffreylifson immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT michaelpiatak immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT robertgorelick immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT yonghuang immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT yuanerwu immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT priscillayhsue immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT jeffreynmartin immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT stevengdeeks immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT josephmmccune immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial AT peterwhunt immunologiceffectsofmesalamineintreatedhivinfectedindividualswithincompletecd4tcellrecoveryarandomizedcrossovertrial |